In Vivo Imaging of Pancreatic Islet Grafts in Diabetes Treatment

Front Endocrinol (Lausanne). 2021 Mar 2:12:640117. doi: 10.3389/fendo.2021.640117. eCollection 2021.

Abstract

Transplantation of pancreatic islets has potential to offer life-long blood glucose management in type I diabetes and severe type II diabetes without the need of exogenous insulin administration. However, islet cell therapy suffers from autoimmune and allogeneic rejection as well as non-immune related factors. Non-invasive techniques to monitor and evaluate the fate of cell implants in vivo are essential to understand the underlying causes of graft failure, and hence to improve the precision and efficacy of islet therapy. This review describes how imaging technology has been employed to interrogate the distribution, number or volume, viability, and function of islet implants in vivo. To date, fluorescence imaging, PET, SPECT, BLI, MRI, MPI, and ultrasonography are the many imaging modalities being developed to fulfill this endeavor. We outline here the advantages, limitations, and clinical utility of each particular imaging approach.

Keywords: cell therapy; diabetes; imaging; islet transplantation; labeling; microcapsule.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Autoimmune Diseases / immunology
  • Diabetes Mellitus / diagnostic imaging*
  • Diabetes Mellitus / therapy*
  • Diagnostic Imaging / methods*
  • Graft Rejection
  • Humans
  • Islets of Langerhans Transplantation / diagnostic imaging*
  • Magnetic Resonance Imaging
  • Mice
  • Microscopy, Fluorescence
  • Multimodal Imaging
  • Pancreas / diagnostic imaging*
  • Positron-Emission Tomography
  • Tomography, Emission-Computed, Single-Photon
  • Ultrasonography